Home » Newsletters » BioWorld Science

BioWorld Science

April 4, 2006

View Archived Issues

Anthrax antibody therapeutic Anthim completes phase I study

GSK and Pharmacopeia establish drug discovery and development alliance

Phase III study of CellCept in pemphigus vulgaris completes enrollment

CFD Therapeutics formed to advance novel cancer therapeutics

Pro-Pharmaceuticals advances phase II colorectal cancer trial of Davanat plus 5-FU

New series of KDR inhibitors presented by Amgen

Activity of pertuzumab evaluated in advanced ovarian cancer

Studies add to data on stem cell mobilization with AMD-3100

Phase I/II trial finds lenalidomide promising in recurrent epithelial ovarian cancer

Actavis reaffirms proposal to acquire Pliva

MediciNova begins phase I study for urinary incontinence treatment MN-246

Ispinesib fails to meet advancement criteria in platinum-sensitive NSCLC

Proteon Therapeutics raises funding to support development of PRT-201

NitroMed restructures R&D operations

Astellas changes Protopic label in Europe

Toyama and Astellas sign basic licensing agreement for T-3811 in Japan

Santen and Oakwood sign agreement on microsphere-based product for DME

Alfresa and Tanabe Seiyaku to comarket modafinil in Japan

Novel PAI-1 inhibitor from Wyeth presented with phase I studies for thrombosis ongoing

Ipilimumab studied in second-line metastatic melanoma patients

Results of study comparing Emisphere's oral heparin to injectable heparin

Novel agents for metabolic disorders reported in recent patents

Myozyme approved for Pompe disease in Europe

Serono seeks U.S., European approvals for new Rebif formulation

New agents for endocrine-related disorders imparted in recent patent literature

European approval for Erbitux in head and neck cancer

AEterna Zentaris presents preclinical data on ZEN-017, a novel tubulin and topo II inhibitor

VX-001 vaccine well tolerated and effective in phase I study in advanced cancer patients

EC-0225: A folate-targeted chemotherapeutic conjugate from Endocyte

Preclinical data behind ENMD-1198's IND approval presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...